Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Sex Cord Gonadal Stromal Tumor Market

ID: MRFR/MED/17447-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Sex Cord Gonadal Stromal Tumor Market Research Report By Type (Granulosa Cell Tumor, Sertoli Cell Tumor, Others), By Diagnosis (Microscopy, Tumor Marker, Others) and By Treatment (Chemotherapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Sex Cord Gonadal Stromal Tumor Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Type (USD Million)
  49.     4.1.1 granulosa cell tumor
  50.     4.1.2 Sertoli cell tumor
  51.     4.1.3 thecoma
  52.     4.1.4 Leydig cell tumor
  53.     4.1.5 Sertoli Leydig cell tumor
  54.     4.1.6 gynandroblastoma
  55.     4.1.7 Sex Cord Tumor with Annular Tubules (SCTAT)
  56.   4.2 Pharmaceutical, BY Diagnosis (USD Million)
  57.     4.2.1 microscopy
  58.     4.2.2 immunohistochemistry
  59.     4.2.3 tumor marker
  60.     4.2.4 ultrasound
  61.     4.2.5 Magnetic Resonance Imaging (MRI)
  62.     4.2.6 others
  63.   4.3 Pharmaceutical, BY Treatment (USD Million)
  64.     4.3.1 chemotherapy
  65.     4.3.2 radiotherapy
  66.     4.3.3 surgery
  67.     4.3.4 others
  68.   4.4 Pharmaceutical, BY End-User (USD Million)
  69.     4.4.1 hospitals and clinics
  70.     4.4.2 cancer research centers
  71.     4.4.3 research and academic institutes
  72.     4.4.4 others
  73. 5 SECTION V: COMPETITIVE ANALYSIS
  74.   5.1 Competitive Landscape
  75.     5.1.1 Overview
  76.     5.1.2 Competitive Analysis
  77.     5.1.3 Market share Analysis
  78.     5.1.4 Major Growth Strategy in the Pharmaceutical
  79.     5.1.5 Competitive Benchmarking
  80.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  81.     5.1.7 Key developments and growth strategies
  82.       5.1.7.1 New Product Launch/Service Deployment
  83.       5.1.7.2 Merger & Acquisitions
  84.       5.1.7.3 Joint Ventures
  85.     5.1.8 Major Players Financial Matrix
  86.       5.1.8.1 Sales and Operating Income
  87.       5.1.8.2 Major Players R&D Expenditure. 2023
  88.   5.2 Company Profiles
  89.     5.2.1 Bristol-Myers Squibb (US)
  90.       5.2.1.1 Financial Overview
  91.       5.2.1.2 Products Offered
  92.       5.2.1.3 Key Developments
  93.       5.2.1.4 SWOT Analysis
  94.       5.2.1.5 Key Strategies
  95.     5.2.2 Novartis (CH)
  96.       5.2.2.1 Financial Overview
  97.       5.2.2.2 Products Offered
  98.       5.2.2.3 Key Developments
  99.       5.2.2.4 SWOT Analysis
  100.       5.2.2.5 Key Strategies
  101.     5.2.3 Merck & Co. (US)
  102.       5.2.3.1 Financial Overview
  103.       5.2.3.2 Products Offered
  104.       5.2.3.3 Key Developments
  105.       5.2.3.4 SWOT Analysis
  106.       5.2.3.5 Key Strategies
  107.     5.2.4 AstraZeneca (GB)
  108.       5.2.4.1 Financial Overview
  109.       5.2.4.2 Products Offered
  110.       5.2.4.3 Key Developments
  111.       5.2.4.4 SWOT Analysis
  112.       5.2.4.5 Key Strategies
  113.     5.2.5 Pfizer (US)
  114.       5.2.5.1 Financial Overview
  115.       5.2.5.2 Products Offered
  116.       5.2.5.3 Key Developments
  117.       5.2.5.4 SWOT Analysis
  118.       5.2.5.5 Key Strategies
  119.     5.2.6 Eli Lilly and Company (US)
  120.       5.2.6.1 Financial Overview
  121.       5.2.6.2 Products Offered
  122.       5.2.6.3 Key Developments
  123.       5.2.6.4 SWOT Analysis
  124.       5.2.6.5 Key Strategies
  125.     5.2.7 Bayer (DE)
  126.       5.2.7.1 Financial Overview
  127.       5.2.7.2 Products Offered
  128.       5.2.7.3 Key Developments
  129.       5.2.7.4 SWOT Analysis
  130.       5.2.7.5 Key Strategies
  131.     5.2.8 Amgen (US)
  132.       5.2.8.1 Financial Overview
  133.       5.2.8.2 Products Offered
  134.       5.2.8.3 Key Developments
  135.       5.2.8.4 SWOT Analysis
  136.       5.2.8.5 Key Strategies
  137.     5.2.9 Roche (CH)
  138.       5.2.9.1 Financial Overview
  139.       5.2.9.2 Products Offered
  140.       5.2.9.3 Key Developments
  141.       5.2.9.4 SWOT Analysis
  142.       5.2.9.5 Key Strategies
  143.   5.3 Appendix
  144.     5.3.1 References
  145.     5.3.2 Related Reports
  146. 6 LIST OF FIGURES
  147.   6.1 MARKET SYNOPSIS
  148.   6.2 US MARKET ANALYSIS BY TYPE
  149.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  150.   6.4 US MARKET ANALYSIS BY TREATMENT
  151.   6.5 US MARKET ANALYSIS BY END-USER
  152.   6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
  153.   6.7 RESEARCH PROCESS OF MRFR
  154.   6.8 DRO ANALYSIS OF PHARMACEUTICAL
  155.   6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  156.   6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  157.   6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  158.   6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
  159.   6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
  160.   6.14 PHARMACEUTICAL, BY DIAGNOSIS, 2024 (% SHARE)
  161.   6.15 PHARMACEUTICAL, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  162.   6.16 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
  163.   6.17 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
  164.   6.18 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
  165.   6.19 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
  166.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  167. 7 LIST OF TABLES
  168.   7.1 LIST OF ASSUMPTIONS
  169.     7.1.1
  170.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  171.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  172.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  173.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  174.     7.2.4 BY END-USER, 2025-2035 (USD Million)
  175.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  176.     7.3.1
  177.   7.4 ACQUISITION/PARTNERSHIP
  178.     7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

  • granulosa cell tumor
  • Sertoli cell tumor
  • thecoma
  • Leydig cell tumor
  • Sertoli Leydig cell tumor
  • gynandroblastoma
  • Sex Cord Tumor with Annular Tubules (SCTAT)

Pharmaceutical By Diagnosis (USD Million, 2025-2035)

  • microscopy
  • immunohistochemistry
  • tumor marker
  • ultrasound
  • Magnetic Resonance Imaging (MRI)
  • others

Pharmaceutical By Treatment (USD Million, 2025-2035)

  • chemotherapy
  • radiotherapy
  • surgery
  • others

Pharmaceutical By End-User (USD Million, 2025-2035)

  • hospitals and clinics
  • cancer research centers
  • research and academic institutes
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓